-
This paper discusses the clinical utility of impulse and rotor mapping to guide atrial fibrillation (AF) ablation and is a follow-up to the acute observations discussed in Clinical Cardiology Alert several months ago.1 The authors hypothesized that AF is sustained by localized sources that may be targeted during AF ablation procedures.
-
Side effects of finasteride; new ruling on pharmaceutical companies paying generic manufacturers; and FDA actions.
-
Primary percutaneous coronary intervention (PCI) saves lives in patients suffering from ST-elevation myocardial infarction (STEMI).
-
In this paper, the authors perform a systematic review and meta-analysis of published reports comparing anticoagulation management strategies around the time of cardiac rhythm device implantation. Using standard techniques, the authors searched the medical literature and identified studies that assessed two or more anticoagulation strategies around the time of cardiac rhythm device implantation.
-
-
When routinely cultured, essentially all ICU privacy curtains were found to be contaminated with potential pathogens at least some of the time. Recovered organisms included methicillin-resistant staphylococci and vancomycin-resistant enterococci.
-
In this study population with a 2% average risk of a major coronary event per year, LDL cholesterol, apolipoproteins, and LDL particle concentrations had similar and strong associations for major vascular events. The independent predictive value of HDL measures is less clear.
-
Clinical Briefs: Coffee Might be One Less Thing We Have to Worry About; ED, Lower Urinary Tract Symptoms, and Ejaculatory Dysfunction; The Allure of Shared Medical Appointments in Diabetes Care
-
A BETA-3 ADRENERGIC AGONIST HAS BEEN APPROVED FOR the treatment of overactive bladder in adults. Mirabegron differs from other agents approved for this same indication, such as oxybutynin, tolterodine, solifenacin, darifenacin, etc., which are anticholinergic/antimuscarinic agents. Mirabegron is marketed by Astellas Pharma as Myrbetriq.
-